Pink SheetScripMedtech InsightHBW InsightGenerics BulletinIn Vivo

Generics Bulletin

Medtech Insight

Biosimilars Statistical Guidance Reflects Early Development Approach

Sep 22 2017

• By Sue Sutter

Identical twins — Statistically, they are the same.

Related Content

Biosimilar Post-Approval Change Guidance Coming From US FDA

Sep 22 2017

Pfizer v. J&J Sets Stage For Biosimilar Showdown Over Exclusive Contracts

Sep 21 2017

Payers Could Guarantee Biosimilar Market Share, FDA's Gottlieb Suggests

Sep 22 2017

Make Interchangeability Great Again: Biosimilar Switching Studies Need US Comparators

Jan 19 2017

US Comparator Requirement For Interchangeable Biosimilars Would Hurt Industry

Jun 01 2017

FDA’s Inaugural Biosimilar Review Bumpier Than First Appeared

Jun 15 2015

Sandoz Steers Enbrel Biosimilar Away From Equivalence Quandary With Reanalysis

Jul 11 2016

Inflectra Analytical Data Eased FDA's 'Residual Uncertainty' About Remicade Differences

Jul 15 2016

Biosimilar User Fee Agreement Puts FDA On Hook For Delayed Guidances

Sep 22 2016

Related Companies

Pfizer Inc.

Celltrion, Inc.

Johnson & Johnson

Novartis AG

Amgen, Inc.

Additional Topics

United States Biosimilars Research & Development Regulation BioPharmaceutical

More from Biosimilars

More from Products

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window